The cross-linked pentapeptides (2R,7R)-diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((2R,7R)-BVD-74D, (2R,7R)-1) and octanedioyl-bis(Tyr-Arg-Leu-ArgTyr-amide) (2) as well as the pentapeptide Ac-Tyr-Arg-LeuArg-Tyr-amide (3) were previously described as neuropeptide Y Y 4 receptor (Y 4 R) partial agonists. Here, we report on a series of analogues of (2R,7R)-1 and 2 in which Arg 2 , Leu 3 , or Arg 4 were replaced by the respective aza-amino acids. The replacement of Arg 2 in 3 with a carbamoylated arginine building block and the extension of the N-terminus by an additional arginine led to the high-affinity hexapeptide Ac-Arg-Tyr-N ω -[(4-aminobutyl)aminocarbonyl]Arg-Leu-Arg-Tyr-amide (35), which was used as a precursor for a D-amino acid scan. The target compounds were investigated for Y 4 R functional activity in assays with complementary readouts: aequorin Ca 2+ and β-arrestin 1 or β-arrestin 2 assays. In contrast to the parent compounds, which are Y 4 R agonists, several ligands were able to suppress the effect elicited by the endogenous ligand pancreatic polypeptide and therefore represent a novel class of peptide Y 4 R antagonists.
INTRODUCTION
Among the neuropeptide Y (NPY) receptors, designated Y 1 R, Y 2 R, Y 4 R, and Y 5 R, 1 the Y 4 R plays a special role because it preferentially binds pancreatic polypeptide. 2 Compared to the Y 1 R, Y 2 R, and Y 5 R subtypes, fewer ligands by far (e.g., see Figure 1 ) have been reported for the Y 4 R, in particular, highaffinity Y 4 R antagonists are still lacking. 3−6 Y 4 R agonists are considered to be potential antiobesity agents. 7, 8 The diastereomeric mixture of the cross-linked ("dimeric") pentapeptide 1 (BVD-74D), a mimic of the Cterminus of pancreatic polypeptide, was described as a highaffinity Y 4 R agonist, 4 having an effect on food intake in mice. 9 As reported previously, (2R,7R)-1 (note: in the following, positions 2 and 7 refer to the stereo centers in the 2,7-diaminosuberic acid moiety) was, by a factor of 3−10, more potent than (2S,7S)-1, depending on the type of assay. 10, 11 Even though Y 4 R agonists should have higher clinical potential, antagonists are of interest as well, in particular, as pharmacological tools. The pentapeptide 3, 6 a Y 4 R agonist with an affinity in the two-digit nanomolar range (K i = 50 nM), shares the same amino acid sequence with the peptide moieties of 1. The incorporation of cyclic β-amino acids such as (1R,2S)-2-aminocyclopentane-1-carboxylic acid resulted in partial agonism. 6 To investigate the impact of backbone modifications in Y 4 R agonists on functional activity in more detail, additional analogues of (2R,7R)-1, 2, 11 and 3 were prepared. Here, we report on the synthesis of Y 4 R ligands in which aza-amino acids or D-amino acids were introduced. The title compounds were characterized in binding and functional cellular assays with complementary readouts.
2. RESULTS AND DISCUSSION 2.1. Chemistry. Aza-peptides contain at least one amino acid in which the α-carbon atom is replaced by nitrogen. 12 The semicarbazide substructure reduces conformational flexibility. 13, 14 Several studies have revealed that the incorporation of aza-amino acids into bioactive peptides may result in a longer duration of action or higher potencies compared to the parent peptide. 15−17 Aza-peptides can be prepared by the reaction of an N-protected, N′-substituted hydrazine with an isocyanate. 12 However, the synthesis of aza-peptides on a solid phase is compromised by an intramolecular side-reaction of resin-bound isocyanates that results in the formation of hydantoins ( Figure  2A ), lowering the yields of the target compounds and requiring time-consuming purification. 18 To circumvent hydantoin formation, N-Fmoc-aza Two different Fmoc-protected hydrazines were synthesized to mimic the side chains of Orn or Leu, respectively (Scheme 1). 3-Aminopropan-1-ol was Boc-protected and subsequently oxidized under Parikh−Doring conditions using dimethyl sulfoxide (DMSO) as an oxidant to form the aldehyde 7. Condensation of (9H-fluoren-9-yl)methyl hydrazinecarboxylate 8 and the aldehyde 7 or isobutyric aldehyde resulted in hydrazones 9 and 11. Subsequent reduction using sodium cyanotrihydridoborate gave access to the substituted hydrazines 10 and 12.
The benzyl ester-protected amino acids 14−16 were treated with triphosgene to give the respective isocyanates in situ (Scheme 2). Without purification, the isocyanates were treated with hydrazines 10 and 12 affording the benzyl-protected NFmoc-aza 1 -dipeptides in yields >70%. Subsequent ester cleavage by hydrogenation gave access to the N-Fmoc-aza 1 -dipeptides Fmoc-aza-Leu-Arg(Pbf)-OH (17) , Fmoc-aza-Orn-(Boc)-Tyr(tBu)-OH (18) , and Fmoc-aza-Orn(Boc)-Leu-OH (19) . The dipeptides 17−19 were employed in solid phase synthesis under the same conditions as those for the standard Fmoc-protected amino acids, resulting in quantitative coupling efficiencies.
To optimize the coupling of a resin-bound aza 1 -peptide, the model peptide H-Ala-aza-Leu-Arg(Pbf)-NH 2 (20) was synthesized under various conditions (Scheme 3). When 3-[bis- 
Scheme 1. Synthesis of the Hydrazines 10 and 12
a a Reagents and conditions: (a) Boc 2 O, Na 2 CO 3 , tetrahydrofuran (THF), 0°C, 10 min, followed by room temperature (rt), 14 h; (b) sulfur trioxide pyridine complex, DMSO, triethylamine (TEA), CH 2 Cl 2 , 0°C, 1 h, followed by rt, 3 h; (c) Fmoc-Cl, MeCN/H 2 O (1:1), 0°C, 10 min, followed by rt, 12 h; (d) 7, CH 2 Cl 2 , 14 h; (e) isobutyraldehyde, CH 2 Cl 2 , 50 h; (f) sodium cyanotrihydridoborate, CH 2 Cl 2 /MeOH (4:3), 2 M HCl (pH 2−3), rt, 2−6 h.
(dimethylamino)methyliumyl]-3H-benzotriazol-1-oxide hexafluorophosphate/hydroxybenzotriazole (HBTU/HOBt) was used as coupling reagent at 35°C, only 5−10% of the desired products were formed. The same holds for the application of the succinimidyl ester, Fmoc-Ala-OSu. The coupling efficiency was increased to approximately 50% when the 7-azabenzotriazole derivative HATU was used as coupling reagent. The best results (>50% coupling efficiency) were achieved by in situ activation of Fmoc-Ala-OH to the corresponding acyl chloride using triphosgene in THF. Surprisingly, when CH 2 Cl 2 was used as a solvent instead of THF, only minor amounts of 20 were detected.
The dimeric aza-peptide (2R,7R)-26, an aza-Leu analogue of (2R,7R)-1, was prepared from the protected pentapeptide 21 and the diacid (R,R)-24 (Scheme 4). For the preparation of the aza-peptides 27−31, octanedioic acid disuccinimidyl ester (25) was used for cross-linking. Cross-linking of 21 with 25 yielded the dimeric aza-peptide 27, an aza-Leu analogue of 2. Dimerization of the protected peptides 22 and 23 resulted in the aza-peptides 28 and 30 containing ornithine instead of arginine. Subsequently, guanidinylation was performed with N,N′-di-Boc-1H-pyrazole-1-carboxamidine resulting in 29 and 31, which were aza-Arg-containing analogues of 2.
Very recently, we reported that the replacement of Arg 2 with the N ω -carbamoylated arginine 32 ( Figure 3 ) in one of the pentapeptide chains of 2 led to increased Y 4 R affinity. 11 Similarly, 32 was used for the preparation of peptides 33−42 (Figure 4 ), which are analogues of the pentapeptide 3, on an Fmoc-Sieber-PS resin by manual SPPS according to the Fmoc strategy.
Finally, the applicability of 32 to the preparation of cyclic peptides via head-to-side-chain cyclization was investigated. Cyclic peptides are structurally more constrained than their linear counterparts and can mimic secondary structural elements of native peptides or proteins. Additionally, cyclic peptides are less prone to enzymatic degradation. The formation of head-to-tail cyclic peptides is often compromised by rather rigid backbones. However, the side-chain of 32 is very flexible, facilitating an approximation of the activated Cterminus and the terminal amino group. The hexapeptide 43 was prepared on an H-L-Tyr(tBu)-2CT resin followed by global side-chain deprotection (Scheme 5). Cyclization was achieved at a peptide concentration of 1 mM using benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) as coupling reagent. Under these conditions, the formation of peptide dimers was not observed. Figure 5 ) (Table 1, Figure  6 ). 11 The affinities of the aza-peptides 27 (K i = 134 nM), 29 (K i = 52.7 nM), and 31 (K i = 113 nM) were lower than the affinity of the respective reference compound 2 (K i = 3. Among the structural modifications of pentapeptide 3, replacement of the N-terminal acetic acid with octanoic acid (compound 33) resulted in an increase in Y 4 R affinity by a factor of almost six. The replacement of Arg 2 in 3 with the carbamoylated arginine 32 was even more favorable: the affinity of 34 (K i = 19.5 nM) was 17-fold higher than the affinity of its parent compound 3. Extension of the N-terminus by an additional arginine led to a further increase in affinity: the K i value of compound 35 was in the single-digit nanomolar range (K i = 2.87 nM). Up to now, comparable binding data were achieved only in the case of cross-linked or significantly longer linear peptides. The extension of the N-terminus of 3 by an additional arginine alone had almost the same impact on Y 4 R affinity, that is, 36 (K i = 3.43 nM) showed nearly the same affinity as peptide 35. Interestingly, the replacement of the arginine adjacent to the C-terminus with the modified arginine building block 32 was not tolerated (37: K i = 501 nM).
Following the structural optimization of 3, a D-amino acid scan was performed with the hexapeptide 35. Previous studies revealed that C-terminal amidation is crucial for Y 4 R binding of the endogenous ligand hPP. 21 Similarly, the (27)). Functional assays with distal readouts such as the luciferase reporter gene assay can reflect pronounced signal amplifications. It should be taken into account that the incubation period in the luciferase reporter gene assays was 4.5 h compared to 60 min for the arrestin assays and a few seconds in the case of the aequorin assay. Therefore, compounds displaying negligible agonistic activity in assays with proximal readouts may show much higher efficacies in reporter gene assays, as demonstrated, for example, for histamine H 4 receptor ligands. 28 Likewise, (2R,7R)-1, a partial agonist in the Ca 2+ assay and the arrestin assay, appeared as a full agonist in the luciferase assay. 
CONCLUSIONS
The affinity and potency of the Y 4 R partial agonist 3 was considerably increased by the replacement of Arg 2 with the carbamoylated arginine 32 and the introduction of an additional arginine at the N-terminus. Several backbone modifications of the C-terminal tripeptide (e.g., the introduction of aza-amino acids or D-amino acids) of 35 as well as headto-side-chain cyclization changed the quality of action of the linear or dimeric Y 4 R peptide ligands from partial agonism to antagonism. The resulting compounds displayed weaker Y 4 R antagonism than the reported Y 4 R antagonist 4. However, due to their extremely facile synthetic accessibility, linear peptides derived from 35 containing D-amino acids (e.g., 40 (K i = 248 nM)) are promising building blocks for further structural modifications and might pave the way for the development of peptide Y 4 R antagonists with increased affinity.
EXPERIMENTAL SECTION
4.1. Chemistry: General Conditions. Chemicals and solvents were purchased from commercial suppliers and used without further purification unless otherwise indicated. DMF for peptide synthesis, NMP for peptide synthesis, 4-DMAP, sodium cyanotrihydroborate, and HOBt hydrate were from Acros Organics/Fisher Scientific (Nidderau, Germany). FmocSieber-PS resin (0.61 mmol/g), Fmoc-Arg(Pbf)-OH, FmocTyr(tBu)-OH, H-L-Tyr(tBu)-2CT resin (0.68 mmol/g), PyBOP, and HBTU were from Iris Biotech (Marktredwitz, Germany). MeCN for HPLC (gradient grade), Fmoc-Leu-OH, DCC, sulfur trioxide pyridine complex, hydrazine hydroxide, and methanol were from Merck (Darmstadt, Germany). Trifluoroacetic acid, TEA, triphosgene, Fmoc chloride, isobutyraldehyde, DEA, CH 2 Cl 2 , diethyl ether, and Triton X-100 were from Sigma-Aldrich (Deisenhofen, Germany); di-tertbutyl dicarbonate (>97%) and 3-aminopropan-1-ol were from Alfa Aesar (Karlsruhe, Germany). DIPEA (99%) was from ABCR (Karlsruhe, Germany), and Fmoc-Ala-OSu was from Advanced Chemtech (Louisville, KY). Bovine serum albumin (BSA) and bacitracin were from Serva (Heidelberg, Germany) and coelenterazin h was obtained from Biotrend (Cologne, Germany). Human pancreatic polypeptide and porcine NPY were from Synpeptide (Shanghai, China). The synthesis of (2R,7R)-1, 11 24 was previously described. Millipore water was used throughout for the preparation of buffers and HPLC eluents. Stock solutions of test compounds were prepared in Millipore water containing 0.1% TFA. Polypropylene reaction vessels (1.5 or 2 mL) with a screw cap (SudLaborbedarf, Gauting, Germany) were used for small scale reactions (e.g., the preparation of 44) and for the storage of stock solutions. Thin-layer and column chromatography, NMR spectroscopy, mass spectrometry, preparative and analytical 5 Presented are mean values ± SEM from at least three independent experiments (performed in triplicate). n.d.: not determined.
HPLC, as well as freeze-drying were performed as described previously. 11 4.2. Compound Characterization. Compounds were characterized as described previously. 11 Purities determined by reversed-phase high-performance liquid chromatography (RP-HPLC) were >95%.
4.3. Chemistry: Experimental Protocols and Analytical Data. General Procedure for Solid Phase Peptide Synthesis. Peptides were synthesized by manual SPPS using the Fmoc strategy on an Fmoc-Sieber-PS resin or an H-LTyr(tBu)-2CT resin (43) as described with minor modifications. Five milliliters Discardit II syringes (Becton Dickinson, Heidelberg, Germany) were equipped with 35 μm polyethylene frits (Roland Vetter Laborbedarf, Ammerbuch, Germany) and used as reaction vessels. For the coupling of standard D-or Lamino acid to the N-terminus of an amino acid or the amino group of the Fmoc-Sieber-PS resin, DMF/NMP (8:2) was used as solvent. Fmoc amino acids (5-fold excess) were preactivated with HBTU/HOBt/DIPEA (5/5/10 equiv) for 5 min and added to the resin. Double coupling at rt was performed for all standard amino acids for 45 min. The coupling of the arginine building block 32 and the dipeptides 17−19 (3-fold excess, preactivated with HBTU/HOBt/DIPEA (3/3/6 equiv)) was performed at 35°C for 14 h ("single coupling") using anhydrous DMF as solvent. For the coupling of Fmoc amino acids to a resin-bound aza-amino acid, triphosgene was used as the coupling reagent. Triphosgene (1.75 equiv) was dissolved in anhydrous THF and cooled to 0°C. A solution of Fmoc amino acid (5 equiv) and DIPEA (15 equiv) in anhydrous THF was added dropwise causing the formation of a white precipitate. After addition, stirring was continued for 5 min. The suspension was centrifuged and the supernatant was added to the resin. Coupling was performed at 35°C for 12 h.
After coupling was completed, the resin was washed with DMF/NMP and treated with 20% piperidine in DMF/NMP (8:2) at rt (2×) for 10 min to remove the Fmoc group, followed by thorough washing of the resin. (15) . Fmoc-Tyr(tBu)-OH (2 g, 4.35 mmol, 1 equiv), 4-DMAP (53.2 mg, 0.1 equiv), and benzyl alcohol (1 mL, 2.2 equiv) were dissolved in CH 2 Cl 2 (25 mL) and a solution of DCC (943 mg, 1.05 equiv) in CH 2 Cl 2 (6 mL) was added dropwise under ice-cooling. The mixture was stirred at rt for 14 h. After completion of the reaction (monitored by thinlayer chromatography (TLC) (light petroleum/EtOAc 2:1): R f = 0.76), the mixture was filtered, and the filtrate was washed with 0.1 M HCl solution (30 mL) and brine (20 mL). The volume of the organic layer was adjusted to 70 mL with CH 2 Cl 2 , and diethylamine (12 mL) was added for removal of the Fmoc group. After all of the starting material had been consumed, the volatiles were removed on a rotary evaporator, and the residue was taken up in light petroleum/EtOAc (1:1, 10 mL) and subjected to column chromatography (eluent: light petroleum/EtOAc 1:1 → EtOAc/MeOH 4:1). A solution of 14 (145 mg, 0.442 mmol) and DIPEA (450 μL, 2 equiv) in CH 2 Cl 2 (5 mL) was added dropwise under icecooling. The mixture was allowed to warm to ambient temperature under stirring for 30 min. A solution of 12 (200 mg, 1.1 equiv) in CH 2 Cl 2 (2 mL) was added and stirring was continued for 90 min. The mixture was diluted with EtOAc (60 mL) and washed with water. The volatiles were removed under reduced pressure, the residue was taken up in EtOAc/hexane (2:1, 10 mL) and subjected to column chromatography (eluent: EtOAc/hexane (2:1)). The protected intermediate was dissolved in MeOH (10 mL), and Pd/C-catalyst (50 mg) was added. The mixture was stirred vigorously under hydrogen. After completion of the hydrogenation, the solids were removed by filtration through celite, the volume was reduced on a rotary evaporator. 4.3.4. {[1-(9H-Fluoren-9-yl)-12,12-dimethyl-3,10-dioxo-2,11-dioxa-4,5,9-triazatridecan-5-yl]carbonyl}-L-leucine (19) . Triphosgene (52.5 mg, 0.4 equiv) was dissolved in CH 2 Cl 2 (2 mL). A solution of 16 (97.7 mg, 0.442 mmol) and DIPEA (150 μL, 2 equiv) in CH 2 Cl 2 (2 mL) was added dropwise under icecooling. The mixture was allowed to warm to ambient temperature under stirring for 30 min. A solution of 10 (200 mg, 1.1 equiv) in CH 2 Cl 2 (2 mL) was added and stirring was continued for 90 min. The mixture was diluted with EtOAc (40 mL) and washed with water. The volatiles were removed under reduced pressure and the residue was taken up in EtOAc/ hexane (1:1, 10 mL) and subjected to column chromatography (eluent: EtOAc/hexane (1:1), R f = 0.71). The protected intermediate was dissolved in MeOH (10 mL), and Pd/Ccatalyst (30 mg) was added. The mixture was stirred vigorously under hydrogen. After completion of the hydrogenation, the solids were removed by filtration through celite, and the volume was reduced on a rotary evaporator. The desired compound was purified via column chromatography (eluent: CH 2 Note: Inhibition of hPP-induced response appears incomplete, however, concentrations of antagonists higher than those given in the curves could not be applied due to a shortage of the test compounds. There was no intrinsic activity of both compounds in the respective assays when performed in the agonist mode (SI Figures 3, 5 4.3.9. Octanedioyl-bis(Tyr-Arg-aza-Leu-Arg-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (27) . Compound 21 (28.8 mg, 19.2 μmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (600 μL). Compound 25 (2.83 mg, 7.7 μmol) was added, and the mixture was stirred at 35°C for 16 h. Water (10 mL) was added, and the protected intermediate was extracted with CH 2 Cl 2 (2 × 10 mL). The combined extracts were evaporated, and the residue was dried in vacuo. TFA/water (95:5 v/v) (2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 mL) was added followed by lyophilization. The product was purified by preparative HPLC (gradient: 0−20 min: MeCN/0.1% aq TFA 3:97− 42:58, t R = 16.5 min). Lyophilization of the eluate afforded 27 as a white fluffy solid (6.3 mg, 38.3% 4.3.10. Octanedioyl-bis(Tyr-Arg-Leu-aza-Orn-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (28) . Compound 22 (16.7 mg, 12.8 μmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (600 μL). Compound 25 (1.9 mg, 5.1 μmol) was added, and the mixture was stirred at 35°C for 16 h. After addition of water (10 mL), the protected intermediate was extracted with CH 2 Cl 2 (2 × 10 mL). The combined extracts were evaporated, and the residue was dried in vacuo. TFA/ water (95:5 v/v) (2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 mL) was added, followed by lyophilization. 4.3.12. Octanedioyl-bis(Tyr-aza-Orn-Leu-Arg-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (30) . Compound 23 (16.7 mg, 12.8 μmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (600 μL). Compound 25 (1.88 mg, 5.1 μmol) was added, and the mixture was stirred at 35°C for 16 h. After addition of water (10 mL), the protected intermediate was extracted with CH 2 Cl 2 (2 × 10 mL). The combined extracts were evaporated, and the residue was dried in vacuo. TFA/ water (95:5 v/v) (2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 mL) was added followed by lyophilization. Routinely performed examinations for mycoplasma contamination using the Venor GeM Mycoplasma Detection Kit (Minerva Biolabs, Berlin, Germany) were negative for all cell types.
4.4.1. HEK293T-ARRB1-hY 4 R and HEK293T-ARRB2-hY 4 R Cells. The β-arrestin recruitment was quantified by a luciferase complementation assay based on the emerald luciferase (ELuc) from the brazilian click-beetle Pyrearinus termitilluminans. The fusion construct of the human hY 4 R (the hY 4 R cDNA was from cDNA Resource Center, Bloomsburg, PA) and the C-terminal luciferase fragment (hY 4 R-ELucC) was generated using the previously described construct SSTR2-ELucC 31, 32 by replacing the cDNA of SSTR2 with the cDNA of the hY 4 R. HEK293T cells were stably transfected with the pcDNA3.1/myc-HIS (B) vector encoding the β-arrestin isoform 1 or 2, N-terminally fused with the N-terminus of the luciferase (ELucN-ARRB1 or ELucN-ARRB2, respectively) 31 and the pcDNA4/V5-HIS (B) vector encoding hY 4 R-ELucC using G418 (600 μg/mL) and zeocin (40 μg/mL) as selection antibiotics, as previously described for the H 1 R. 33 To determine the hY 4 R-ELucC expression, saturation binding studies were performed with both HEK293T-ARRB1-hY 4 R cells and HEK293T-ARRB2-hY 4 R cells using the radioligand 45 (cf. SI Figures S6 and S7) 26 and HEK293T-hY 4 R-CRE Luc cells 11 were cultured as described previously. HEK293T-ARRB1-hY 4 R and HEK293T-ARRB2-hY 4 R cells were maintained in Dulbecco's modified Eagle's medium containing 10% FCS, 600 μg/mL G418, and 40 μg/mL zeocin.
4.6. Radioligand Binding Assays. Radioligand binding assays at all NPY receptor subtypes were performed at 22 ± 1°C according to the experimental protocols described in detail previously.
11 Radioactivity (dpm) was measured with a MicroBeta2 plate counter (PerkinElmer, Rodgau, Germany). Cells, buffers, radioligands, and the respective K d values and concentrations, as well as the assay conditions are summarized in Table 3 .
4.7. Fura-2 Calcium Assay. The assay was performed with HEL cells as previously described. 34, 35 4.8. Aequorin Calcium Assay. The assay was performed on CHO-hY 4 -G qi5 -mtAEQ cells as previously described 26 using a GENios Pro plate reader (Tecan, Salzburg, Austria). Areas under the curve were calculated using SigmaPlot 12.5 software (Systat Software Inc., Chicago, IL).
4.9. Luciferase Assay. The Luciferase assay was performed on HEK293-hY 4 -CRE Luc cells as previously described. 4.10. β-Arrestin Recruitment Assay. The recruitment of β-arrestin was measured via the split-luciferase complementation technique. 32 Agonist potencies were determined on HEK293T-ARRB1-Y 4 R and HEK293T-ARRB2-Y 4 R cells using the GENios Pro microplate reader (Tecan, Salzburg, Austria) as previously described for HEK293T-ARRB1-H 1 R and HEK293T-ARRB2-H 2 R, respectively. 33 For the determination of antagonism, the cells were preincubated in the presence of the antagonist for 15 min. Ten microliters of an hPP solution (30 nM, final concentration 3 nM) was added and incubation was continued at 25°C for 60 min. The plates were further processed as in the case of the agonist mode.
4.11. Data Analysis. Concentration response curves from functional assays and displacement curves from radioligand competition binding were analyzed by four-parameter sigmoidal fits (GraphPad Prism 5.0, San Diego, CA). Agonist potencies are given as EC 50 values, intrinsic activities are expressed as α values with respect to the effect of 1 μM hPP (maximal response α = 1.0). Antagonistic activities were determined in the presence of 3 nM hPP (β-arrestin 1/2 assay, EC 50 = 3.54 nM (ARRB1), EC 50 = 2.74 nM (ARRB2)), 100 nM hPP (aequorin assay, EC 50 = 9.7 nM) or 10 nM pNPY (Fura-2 Ca 
